- BioScrip (BIOS +18.5%) shares surge following renewed M&A speculation on the back of this morning's CVS acquisition of Coram for $2.1B.
- Market chatter is referencing Jefferies' opinion the BioScrip could realistically fetch $12-$14/share, an 83% premium from the current price.
- The stock has been downtrodden as of late, with shares having fallen 66.5% into yesterday's close from June highs.
BioScrip surges on M&A speculation following CVS Coram acquisition
Nov 27 2013, 10:13 ET